Madrigal Pharmaceuticals (MDGL) PT Raised to $193 at Canaccord Genuity, Following Earnings
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Price: $507.56 +0.04%
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity analyst Edward Nash raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $193.00 (from $179.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- KP Tissue Inc. (KPT:CN) (KPTSF) PT Raised to Cdn$13.50 at Desjardins
- Libra Energy Materials options two Quebec lithium projects near Cisco
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Earnings, Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
